Aprea Therapeutics, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Aprea announced strengthening of its intellectual property portfolio across two core programs: WEE1 kinase inhibitor (APR-1051, in Phase 1 ACESOT-1051 trial) with patent protection extending to 2047; and ATR inhibitor (ATRN-119) with protection to 2035-2037 (pending applications potentially to 2045). The company closed the ATRN-119 dose-escalation study after determining RP2D of 1,100 mg once daily in 2025, pivoting to evaluate combination approaches. No financial transactions, partnerships, or material business changes announced.
Why this rating
IP portfolio expansion is routine for clinical-stage biotech; no new partnerships, financing, or clinical breakthroughs announced. Standard patent maintenance relative to $8.6M market cap.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.